Clinical Research Directory
Browse clinical research sites, groups, and studies.
Nebulized Verapamil in COPD Exacerbations
Sponsor: Ain Shams University
Summary
This clinical trial evaluated whether adding nebulized verapamil to conventional treatment could improve oxygenation and clinical status in patients hospitalized with an acute exacerbation of chronic obstructive pulmonary disease (COPD). A total of 60 participants were randomly assigned to two groups. One group received nebulized verapamil in addition to conventional treatment, while the other group received conventional treatment alone. Nebulized verapamil was given at a dose of 10 mg twice daily for three consecutive days. The study assessed changes in oxygenation, respiratory function, symptoms, functional status, and cardiovascular safety during the treatment period.
Official title: Effect of Nebulized Verapamil on Oxygenation in Chronic Obstructive Pulmonary Disease (COPD) Exacerbation Patients
Key Details
Gender
All
Age Range
41 Years - Any
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2023-04-30
Completion Date
2024-03-30
Last Updated
2026-10-09
Healthy Volunteers
No
Conditions
Interventions
Verapamil hydrochloride
Verapamil hydrochloride was administered by nebulization at a dose of 10 mg twice daily for 3 consecutive days, for a total of 6 scheduled doses. Each dose was prepared from two 5-mg ampoules at a concentration of 2.5 mg/mL, providing a total volume of 4 mL, and was administered using a compressed-air jet nebulizer.
Conventional treatment
Conventional treatment for acute exacerbation of COPD included antibiotics and bronchodilators and was administered during the 3-day study period.
Locations (1)
Ain Shams University Hospitals
Cairo, Cairo Governorate, Egypt